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ABSTRACT Vitiligo is an acquired, pigmentary skin disorder that af-
fects about 0.1-4.0% of the population. In this study, we aimed to 
investigate the disease features such as age of onset, disease dura-
tion, clinical and sociodemographic characteristics, and laboratory 
parameters of patients with vitiligo. A hundred patients who were 
in follow-up for vitiligo between the period of June 2013 and May 
2014 were included in the study. The clinical features and labora-
tory parameters were retrospectively obtained from the records of 
the patients. The mean age was 34.9±16.8 years. The most common 
clinical types were focal and acrofacial. Facial involvement was the 
most common localization. Forty-five (45%) patients had an asso-
ciated systemic disease. Autoimmune thyroid disease, essential hy-
pertension, and alopecia  areata, which were observed in 28%, 8%, 
and 5% of patients, respectively, were the most common associated 
diseases. Twenty-one percent of the patients had low ferritin levels, 
20% had low iron levels, 12% had low vitamin B12 levels, and 1% 
had low folic acid levels. The prevalence of anti-TG (anti-thyroglobu-
lin) and anti-TPO (anti-thyroid peroxidase) antibodies were found 
17% and 27% of the patients, respectively. We found that the clini-
cal characteristics of vitiligo in our patients were similar to those in 
other studies. We observed laboratory abnormalities and accompa-
nying diseases associated with vitiligo. Therefore we conclude that 
laboratory examinations including thyroid antibodies and regular 
follow-up of these patients are essential.
KEY WORDS: vitiligo, sociodemographic characteristics, autoimmu-
nity, thyroid antibodies
INTRODUCTION
Vitiligo is a disorder characterized specifically 
by melanocyte destruction and clinically by depig-
mented macules which can either be hereditary or 
acquired (1). Its prevalence is approximately 1% (2). 
In Turkey, the frequency of vitiligo is reported as 0.15-
0.32% (3). Although can be found in every age group, 
50% of the cases are younger than 20 and 70-80% of 
the cases are under the age of 30 (4). The etiology of 
the disease is not clear, but genetic predisposition, 
autoimmunity, and toxic metabolites are thought to 
be responsible for the pathogenesis of the disease 
(5).
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In the literature there are several studies evaluat-
ing the relation of vitiligo with other autoimmune 
disorders, laboratory parameters, clinical features of 
different age populations, and genetic predisposi-
tion. In this study, our aim was to evaluate the age of 
onset of the disease, family history, the extent of the 
involvement, sex, as well as the association with other 
disorders in patients with vitiligo, in order to report 
the clinical properties and laboratory parameters in 
Turkish population. 
PATIENTS AND METHODS
The data of the 100 patients with vitiligo treated in 
our clinic between June 2013 and May 2014 were ret-
rospectively evaluated. Age, sex, type of the disease, 
distribution of the lesions, the age of onset, family his-
tory (in the first, second and third-degree relatives), 
accompanying diseases, systemic and topical treat-
ments, and laboratory parameters are recorded for 
all of the patients. The patients who had new lesions 
or had extending lesions in the last 3 months were 
reported as ‘‘active’’, and the patients showing no dif-
ference in their lesions were reported as ‘‘stable’’.
According to their clinical involvement, patients 
were subdivided into six groups: focal, acrofacial, 
generalized, segmental, mucosal, and universal. The 
levels of hemoglobin and iron, vitamin B12, folic acid, 
anti-thyroglobulin antibody (anti-TG), anti-peroxidase 
antibody (anti-TPO), thyroid stimulating hormone 
(TSH), free thyroiodothyronine (fT3), free thyroxine 
(fT4), hepatitis B antibodies (anti-HBV), hepatitis C 
antibody (anti-HCV), and anti-HIV antibodies were 
recorded as the laboratory parameters.
Regarding the descriptive statistics of the data, 
mean, median, standard deviation, minimum-maxi-
mum, ratio, and frequency levels were used. The dis-
tribution of the parameters was controlled by the Kol-
mogorov-Smirnov test. For the analysis of the quanti-
tative data, Kruskal-Wallis, Mann-Whitney U test, and 
independent samples t-test were used. Chi-square 
test was used for quantitative analysis, and for the 
data for which the chi-square test was not appropri-
ate, the Fisher’s exact test was used. The results with 
P values of  <0.05 were defined as statistically signifi-
cant. The SPSS 22.0 (Armonk, NY: IBM Corp) program 
was used for the analysis of the data. This study has 
been approved by the research ethics committee of 
the Okmeydani Training and Research Hospital.
RESULTS
A hundred patients with vitiligo were recruited in 
our study. Forty-nine of the patients were women and 
51 were men. The age of the patients were between 3 
and 78 (mean age (± standard deviation): 34.9±16.8). 
Twelve (12%) of the patients were children (≤15 
years of age) and 84 (84%) of them were adults (≥15 
years of age). The age of onset of the disease had a 
wide range, between 2 and 73 (mean age of onset: 
30.2±16.9). The mean age of onset was 30.0±17.4, 
30.3±16.6 in female and male patients, respectively. 
The duration of the disease ranged between 1 month 
and 39 years (the mean duration: 4.9±6.7 years). The 
age of onset of the disease, the duration of the dis-
ease, the distribution of the involvement types, the 
family history, the accompanying diseases, and the 
ratio of autoimmune disorders showed no statistical-
ly significant difference between the sexes (P>0.05). 
A positive family history was present in 27% of the 
patients (in 11% of them in first-degree relatives, in 
12% of them in second-degree, and in 10% in third-
degree relatives). The disease was active in 82% of the 
patients and stable in 18%.
The distribution of the lesions was as follows: fa-
cial involvement 72%, upper extremities 69%, lower 
extremities 64%, trunk 39%, and anogenital region 
31%. The clinical types were focal in 39%, acrofacial 
Table1. Clinical features and demographic characteristics of patients with vitiligo
Women (n) Men (n) Women (%) Men (%) P





Disease duration (mean±SD (range)) 5.7±7.9 4.1±5.1 0.512
Forms of disease 
Focal 22 17 43.1 34.7 0.4
Generalized 15 11 29.4 22.4
Acrofacial 12 19 23.5 38.8
Universal 2 2 3.9 4.1
Family history 14 13 27.5 26.5 0.917
Associated autoimmune disorders 20 15 39.2 30.6 0.367
*SD: Standard deviation
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in 31%, generalized in 26% and universal in 4% of 
the patients. The clinical features of the patients are 
shown in Table 1.
Forty-five percent of the patients had an accom-
panying systemic disease. The most common disease 
was autoimmune thyroid disorder (28%) and the oth-
ers were essential hypertension (8%) and alopecia 
areata (5%) (Table 2). The frequency of autoimmune 
diseases was 35%. Systemic diseases were found in 
38.4% of the patients with generalized vitiligo and 
in the 17.9% of the patients with focal vitiligo. Four 
percent of the patients had a malignancy. These ma-
lignancies were cranial tumor, leukemia, and breast 
cancer.
The age of onset of the diseases did not show a 
significant correlation with the type of the involve-
ment, family history, or the presence of an autoim-
mune disorder (P>0.05).
Focal disease had a significantly slower disease 
course in comparison with the generalized, acrofacial, 
and universal forms (P=0.001). Between the general-
ized, acrofacial, and universal forms, the difference in 
the duration of the disease was not statistically sig-
nificant (P>0.05).
In our study, the possibility of a patient having at 
least one positive thyroid antibody was found to be 
36%. Positive anti-TPO was found in 27% of the pa-
tients, and 17% of them were anti-TG positive (Table 
3). The positivity of the autoantibodies had the same 
frequency in both sexes. Among these patients, 14% 
of them had focal, 10% had acrofacial, 9% had gen-
eralized, and 1% had universal vitiligo. Twenty-eight 
percent of patients with positive autoantibodies had 
autoimmune thyroiditis, and 15% of these patients 
were hypothyroid while 85% were euthyroid. Autoim-
mune thyroiditis was present in 23% of the patients 
with generalized vitiligo and in 12% of the patients 
with focal vitiligo.
When other laboratory parameters were evalu-
ated, 21% of the patients had lower ferritin, 12% had 
lower B12, and 1% had lower folic acid levels. Three 
percent of the patients had positive viral markers (2 
had anti-HBV, 1 had anti-HCV positivity). The frequen-
cy of anemia was 15% (Table 3). 
Fifty two percent of the patients were given lo-
cal treatments (topical steroids (31%), pimecrolimus 
(13%), tacrolimus (10%), herbal therapies (4%)) while 
14% had systemic treatments (Narrow band ultravio-
let B (UVB) and psoralen combined with ultraviolet A 
PUVA (13%), cyclosporine (1%)).  
DISCUSSION
Vitiligo is a pigmentation disorder characterized 
by depigmented macules due to melanocyte destruc-
tion which affects the skin, hair, and mucosa. Patients 
may have emotional stress or social stigmatization 
due to cosmetic reasons (6,7). 
The incidence of vitiligo differs among countries. 
In Denmark the incidence of the disease is 0.36%, in 
Lebanon it is 0.33%, and in China the incidence was 
reported as 0.093% (8,9). The highest incidence was 
found in Nigeria with 6% (6).
Although vitiligo can be found in both sexes, in 
some studies it was reported to be more common in 
women due to cosmetic reasons (6,8). In our study, 
male and female ratios were quite similar, and this 
finding is consistent with the findings of Lu et al. and 
Gönül et al. (9,10)
The onset of vitiligo has varied among different 
studies. Results of a study by Gönül et al. showed that 
29% of their patients were aged under 30 (10). Prad-
han et al. reported that the majority of the patients 
had onset of the disease under the age of 25 (11). In 
our study, 20% of our patients had onset of the dis-
ease before 20 years of age. 
In Sigh’s vitiligo study, the ages of the patients 
Table 2. Vitiligo-associated diseases
n (%) Men/Women
Autoimmune thyroid disorder 28 10/18
Essential hypertension 8 3/5
Alopecia areata 5 2/3
Malignancy 4 1/3
Asthma 3 1/2
Type 2 diabetes mellitus 2 0/2
Psoriasis 2 1/1




Pernicious anemia 1 1/0
Others 6
Table 3. Laboratory findings of patients with 
  vitiligo
Laboratory parameters n (%)
Decreased ferritin level 21
Decreased iron levels 20
Decreased vitamin B12 levels 12
Decreased folate levels 1
Anemia 15
Positivity of viral markers 3
Positivity of anti-TPO 27
Positivity of anti-TG 17
Positivity of thyroid antibodies (anti-TPO or 
anti-TG)
36
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ranged between 10 months and 58 years (12); in 
Onunu’s study, the age range was between 9 months 
and 80 years (6). Lu et al. reported that 69% of the pa-
tients were between 15 and 64 years of age (9). Gönül 
et al. reported the mean age for the patient popu-
lation as 37.4 (10). In our study, the age-range was 
between 3 months and 78 years (the mean age was 
34.9). Our findings were similar to previous studies. 
Vitiligo has been observed in the pediatric popu-
lation as well. In a study performed in India, 625 pe-
diatric patients were recruited and the mean age at 
the time of diagnosis was reported as 6.2; the most 
common form of vitiligo was generalized vitiligo (13). 
In our study, there were 12 (12%) patients under the 
age of 15, and the most common form was focal viti-
ligo (8%). 
In our study, 82% of the patients had the ‘‘active’’ 
form of the disease. Zhang et al. analyzed 6516 pa-
tients, and the active form of the disease was report-
ed in the 32% of the patients, whereas in Gönül et al. 
found the ratio to be 44% (10,14).
More than 30% of vitiligo cases are known to have 
an affected relative and 21% to have an affected first-
degree relative (15). Previous reports have reported 
the incidence of a family history at between 12 % and 
36 % of patients (11). Handa et al., similar to our find-
ings, found that 11.5% of the patients had a family 
history in first-degree relatives (13). In Japan, family 
history was observed in 3.4% (16). In our study, the 
overall family history in first, second, and third-de-
gree relatives was recorded in 27% of patients. This 
higher ratio may be due to the fact that consanguine-
ous marriages are common in our country.
Where clinical forms are concerned, in Japan the 
most common forms were generalized, focal, and 
segmental, whereas the generalized form was most 
common in Libya (12,16). Lu et al. reported 28% gen-
eralized, 26% focal, and 12.4% acrofacial vitiligo (9). In 
the present study, in contrast to previously published 
reports, focal vitiligo was the most common clinical 
type, followed by acrofacial and generalized forms. 
This can be explained by more patient awareness of 
the cosmetic disfigurement, therefore making them 
more likely to seek treatment.
Gönül et al. reported that the most common site 
of involvement was the face and the upper extremi-
ties (10). Yoshida et al. reported higher frequencies 
of face, chest, and abdomen involvement (16). In our 
study, the most common lesions sites were the face 
and the upper extremities. The higher incidence of 
facial involvement is thought to be due to sunlight 
exposure and physical trauma, which may play role in 
the pathogenesis of the disease.
Vitiligo has been reported to be accompanied by 
pernicious anemia, Addison’s disease, diabetes mel-
litus, myasthenia gravis, scleroderma, rheumatoid ar-
thritis, alopecia areata, autoimmune thyroid diseases, 
and many others (17). Most of these disorders are au-
toimmune in origin. There were also some changes in 
humoral and cellular immunity in molecular studies 
of vitiligo, which are said to play role in the disease 
pathogenesis. In one of the studies from Turkey, there 
were IgG and C3 deposition in the basal membranes 
and keratinocytes of the vitiligo lesions, which are 
consistent with autoimmunity (18). In Zheng’s study, 
more common autoimmune disorders seen in vitiligo 
patients were rheumatoid arthritis, hyperthyroidism, 
hypothyroidism, alopecia areata, and chronic urti-
caria. In familial vitiligo cases, diabetes, thyroid disor-
ders, and rheumatoid arthritis were common (14). In 
our study, thyroid disorders, essential hypertension, 
and alopecia areata were the most common accom-
panying disorders. In familial vitiligo cases the most 
common disorders were autoimmune thyroid disor-
der and alopecia areata. Gönül et al. reported that the 
most common systemic disorders were autoimmune 
thyroid disease, diabetes mellitus, and essential hy-
pertension (10). In recent studies, some evidence has 
shown that T lymphocytes play a role in the etiology 
of essential hypertension. Guzik et al. proved that an-
giotensin II-induced hypertension never develops in 
rats which do not have lymphocytes. Researchers also 
noted that the periaortic tissue showed lymphocytic 
infiltration in cases of angiotensin II-induced hyper-
tension, and that local cytokine production may play 
role in the change of the vascular reaction (19). All 
these results show that essential hypertension may 
also be an autoimmune disorder just like vitiligo. Fur-
ther studies are needed to prove this hypothesis.
Akay et al. reported that 55% of vitiligo patients 
had autoimmune disorders (Hashimoto thyroiditis 
31.0%, alopecia areata 12.5%, pernicious anemia 
8.7%, and diabetes mellitus 2.5%) (20). In our study, 
35% of the patients had autoimmune disorders (au-
toimmune thyroid disorder 28%, alopecia areata 8%, 
psoriasis 2%, pernicious anemia 1%, immunothrom-
bocytopenic purpura 1%).
Thyroid dysfunction and thyroid autoantibody 
positivity were present in varying amounts in patients 
with vitiligo (21). Thyroid dysfunction may be sub-
clinical or may reach the clinically meaningful grades, 
and these patients may be diagnosed with Graves’ 
disease, Hashimoto thyroiditis, hypothyroidism, or 
hyperthyroidism. This finding indicates the need for 
regularly evaluating these patients by means of thy-
roid dysfunction and thyroid-related antibodies. It is 
known that anti-TPO positivity in Turkey is around 
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7-8% (18). Akay et al. (Turkey) found 31% positive 
anti-TPO in the patient group with vitiligo. Yang et al. 
reported 24.1% positive anti-TPO and 23% anti-TG in 
their patient population (20,21). In our study, the rate 
of a patient having at least one positive thyroid anti-
body was found to be 36%. Thyroid antibodies were 
most commonly found in patients with focal vitiligo. 
Twenty-eight percent of these patients having posi-
tive autoantibodies had autoimmune thyroiditis, and 
15% of these patients were hypothyroid while 85% 
were euthyroid. Autoimmune thyroiditis was most 
commonly found in patients with generalized viti-
ligo.
The frequency of diabetes mellitus was reported 
as 1-7% in patients with vitiligo. Both of the disor-
ders are associated with HLADR3 and HLADR4. T lym-
phocytic stimulation against pancreas islet cells and 
therefore firing of inflammatory response were attrib-
uted to the pathogenesis of type 1 diabetes mellitus. 
Long-lasting diabetes mellitus is thought to increase 
the release of antigenic materials, and this may lead 
to melanocyte destruction and inhibition of mela-
nogenesis; this whole process may play a role in the 
pathogenesis of vitiligo. In our study, the frequency 
of type 2 diabetes mellitus was found to be 2% (22).
Free radicals may be toxic for melanocytes and 
may cause harm. This mechanism may also play role 
in the pathogenesis of vitiligo (23). Nitric oxide is an 
enzyme causing melanocyte loss. Iron binds to the 
cofactor of this enzyme and therefore decreases its 
activity. In vitiligo cases, repigmentation is observed 
after the treatment of iron-deficiency anemia. This 
finding has induced researchers to evaluate the 
iron and ferritin depots in vitiligo cases (24). A Turk-
ish study performed by Mansur et al. found no sig-
nificant difference between the patient and control 
group in serum iron and ferritin (24). Gönül et al. 
found a, decrease in ferritin and iron levels by 20.4% 
and 27.2%, respectively (25). In our study, these levels 
were found to be 21% and 20%, respectively. There 
are studies evaluating vitamin B12 and folic acid lev-
els in patients with vitiligo. Gönül et al. found vitamin 
B12 deficiency in patients with vitiligo to be 6.8%, 
whereas folic acid deficiency was 4.5% (25). However, 
when the control and patient groups were compared, 
there was no significant difference reported. Vitamin 
B12 deficiency was 12% and folic acid deficiency was 
1% in our patients. We did not have a control group 
and therefore we cannot reach further conclusions 
on this subject. 
There are studies showing that hepatitis viruses 
play a role in some autoimmune diseases such as li-
chen planus, mixed cryoglobulinemia, and psoriasis. 
In recent studies, hepatitis C virus (HCV) seropositiv-
ity was reported in some patients with vitiligo (26). 
A hundred and two vitiligo cases were evaluated by 
means of HCV seropositivity; anti-HCV was reported 
to be positive in 0.98% of the cases in a Turkish study 
(27). Our findings are consistent with this study, since 
anti-HCV positivity was only 1%. Akcan et al. evaluat-
ed hepatitis B (HB) prevalence in patients with vitiligo 
as well as hepatitis B surface antigen; anti-HBs posi-
tivity was found to be less in the patient population in 
comparison with the healthy controls (28). Hepatitis 
B surface antigens were positive in one patient in our 
study. These results indicate that hepatitis viruses do 
not play a role in the pathogenesis of the disease.
CONCLUSIONS
Vitiligo is a multifactorial disorder in which genet-
ic and environmental factors play a role. In our study, 
we found that the prevalence of vitiligo was at a simi-
lar ratio in both sexes, and the most common form 
of vitiligo was the focal form. Family history of the 
disease was frequently found in our patient group. 
In some of our patients, accompanying diseases such 
as autoimmune thyroid disorders, hypertension, and 
alopecia areata were found, and furthermore some of 
the laboratory parameters were at abnormal values. 
Therefore it can be said that vitiligo is not only a cos-
metic issue. In our opinion, clinicians should pay ex-
tra attention to patients with a positive vitiligo family 
history and should inform them about the possible 
harmful effects of sun-exposure as well as monitor 
those patients, especially with thyroid autoantibody 
testing and also with other laboratory tests. 
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